$SMMT
Summit Therapeutics Inc.

2022 Q3 Form 10-Q Financial Statement

#000159929822000095 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $220.0K $235.0K $250.0K
YoY Change -83.19% 312.28% 30.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.573M $6.933M $6.659M
YoY Change -1.57% 15.86% 59.12%
% of Gross Profit
Research & Development $17.05M $9.008M $20.56M
YoY Change -14.51% -62.35% 11.85%
% of Gross Profit
Depreciation & Amortization $310.0K $331.0K $69.00K
YoY Change -8.01% -4.61% -13.75%
% of Gross Profit
Operating Expenses $22.62M $15.94M $27.22M
YoY Change -11.65% -46.7% 20.61%
Operating Profit -$16.94M -$12.69M -$22.16M
YoY Change -13.07% -46.51% 30.93%
Interest Expense $692.0K $653.0K -$152.0K
YoY Change 202.31% 462.96%
% of Operating Profit
Other Income/Expense, Net -$4.445M -$4.079M $761.0K
YoY Change 3833.63% 494.61% -234.69%
Pretax Income -$21.39M -$16.77M -$21.40M
YoY Change 9.11% -31.31% 22.35%
Income Tax
% Of Pretax Income
Net Earnings -$21.39M -$16.77M -$21.40M
YoY Change 9.11% -31.31% 22.35%
Net Earnings / Revenue -9720.45% -7136.6% -8558.8%
Basic Earnings Per Share -$0.14 -$0.17 -$0.22
Diluted Earnings Per Share -$0.14 -$0.17 -$0.22
COMMON SHARES
Basic Shares Outstanding 98.12M shares 99.65M shares 98.07M shares
Diluted Shares Outstanding 148.6M shares 99.65M shares 98.07M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.0M $57.34M $77.45M
YoY Change 51.99% -44.54% -24.21%
Cash & Equivalents $122.0M $57.34M $77.45M
Short-Term Investments
Other Short-Term Assets $428.0K $2.300M $1.475M
YoY Change -64.06% 138.84% 49.75%
Inventory
Prepaid Expenses $1.622M $5.393M $4.350M
Receivables $140.0K $238.0K $870.0K
Other Receivables $12.96M $14.13M $15.29M
Total Short-Term Assets $137.1M $79.40M $99.44M
YoY Change 34.15% -34.64% -20.59%
LONG-TERM ASSETS
Property, Plant & Equipment $930.0K $1.095M $965.0K
YoY Change 41.77% 44.65% 41.08%
Goodwill $1.655M $1.806M $1.953M
YoY Change -17.25% -12.2% -4.59%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $140.0K $179.0K $166.0K
YoY Change
Total Long-Term Assets $18.21M $16.32M $17.04M
YoY Change -31.19% -32.1% 9.37%
TOTAL ASSETS
Total Short-Term Assets $137.1M $79.40M $99.44M
Total Long-Term Assets $18.21M $16.32M $17.04M
Total Assets $155.3M $95.72M $116.5M
YoY Change 20.71% -34.22% -17.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.431M $3.574M $6.959M
YoY Change -75.64% -48.57% 69.15%
Accrued Expenses $11.14M $5.513M $7.569M
YoY Change 49.91% -10.09% 54.0%
Deferred Revenue $0.00 $3.231M $5.097M
YoY Change -100.0% -54.75% -31.34%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.68M $15.17M $22.72M
YoY Change -26.8% -30.68% -68.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $25.31M $25.06M
YoY Change
Other Long-Term Liabilities $2.424M $2.594M $2.751M
YoY Change -9.89% -3.53% 5.69%
Total Long-Term Liabilities $2.424M $2.594M $2.751M
YoY Change -9.89% -3.53% 5.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.68M $15.17M $22.72M
Total Long-Term Liabilities $2.424M $2.594M $2.751M
Total Liabilities $22.08M $44.40M $52.07M
YoY Change -16.29% 70.18% -31.84%
SHAREHOLDERS EQUITY
Retained Earnings -$359.1M -$337.7M -$320.9M
YoY Change 31.83% 33.54% 40.52%
Common Stock $2.013M $981.0K $981.0K
YoY Change 106.25% 0.72% 18.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $133.2M $51.32M $64.41M
YoY Change
Total Liabilities & Shareholders Equity $155.3M $95.72M $116.5M
YoY Change 20.71% -34.22% -17.27%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$21.39M -$16.77M -$21.40M
YoY Change 9.11% -31.31% 22.35%
Depreciation, Depletion And Amortization $310.0K $331.0K $69.00K
YoY Change -8.01% -4.61% -13.75%
Cash From Operating Activities -$8.555M -$19.22M -$19.00M
YoY Change -63.7% 0.22% -8.07%
INVESTING ACTIVITIES
Capital Expenditures $20.00K -$293.0K $361.0K
YoY Change 400.0% 94.04% 825.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $20.00K -$293.0K -$361.0K
YoY Change 400.0% 94.04% 825.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.00M 0.000 $25.19M
YoY Change 10994.23% -100.0% -54.94%
NET CHANGE
Cash From Operating Activities -8.555M -19.22M -$19.00M
Cash From Investing Activities 20.00K -293.0K -$361.0K
Cash From Financing Activities 75.00M 0.000 $25.19M
Net Change In Cash 66.46M -19.51M $5.659M
YoY Change -390.42% -2677.28% -84.18%
FREE CASH FLOW
Cash From Operating Activities -$8.555M -$19.22M -$19.00M
Capital Expenditures $20.00K -$293.0K $361.0K
Free Cash Flow -$8.575M -$18.92M -$19.36M
YoY Change -63.62% -0.52% -6.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001599298
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36866
dei Entity Registrant Name
EntityRegistrantName
Summit Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1979717
dei Entity Address Address Line1
EntityAddressAddressLine1
2882 Sand Hill Road, Suite 106
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
514-7149
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
SMMT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98122356 shares
CY2022Q2 us-gaap Cash
Cash
57335000 usd
CY2021Q4 us-gaap Cash
Cash
71791000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Business and Operations and Recent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms "Summit" and the "Company" refer to Summit Therapeutics Inc. and its subsidiaries. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet healthcare needs. The Company's novel pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines. The Company's lead product candidate, ridinilazole, is a novel first-in-class drug that is engaged in a global Phase III clinical trial program. On December 20, 2021, the Company announced topline results for the Phase III Ri-CoDIFy study evaluating ridinilazole for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI. The Company's second product candidate, SMT-738, was announced in May 2021 for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (“CRE”) infections. SMT-738 is the first of a novel class of precision antibiotics that has entered into preclinical development. The Company has two additional discovery-phase assets in its pipeline with undisclosed targets in the therapeutic area of oncology. The Company intends to expand its pipeline portfolio by developing further new era product offerings in the therapeutic area of oncology and/or product offerings that are designed to work in harmony with the human gut microbiome.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 22, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its common stock. The rights offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds from the rights offering were $100,000 from the sale of approximately 103,000,000 shares of the Company's common stock at a price of $0.97 per share. Issuance costs were approximately $100. In connection with the closing of the rights offering, the 2022 Note, which is defined in Note 11, matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering on August 10, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 27, 2022, the Company held a Special Meeting of Stockholders (the "Special Meeting") whereby the following matters were submitted to a vote of the Company’s stockholders at the Special Meeting: (i) an amendment to the Company’s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”) to increase the number of shares of the Company’s common stock issuable under the Plan by 8,000,000 shares.</span></div>Each of the matters submitted to a vote of the Company’s stockholders at the Special Meeting was approved by the requisite vote of the Company’s stockholders in accordance with the recommendation of the Company’s Board of Directors.
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
238000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1464000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5393000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7161000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2300000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1201000 usd
CY2022Q2 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
14132000 usd
CY2021Q4 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
15695000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
79398000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
97312000 usd
CY2022Q2 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
2323000 usd
CY2021Q4 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
0 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1095000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
694000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2017000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation and Use of Estimates<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. All intercompany accounts and transactions have been eliminated in consolidation. The interim financial data as of June 30, 2022, and for the three and six months ended June 30, 2022 are unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The condensed consolidated balance sheet presented at December 31, 2021 has been derived from the consolidated audited financial statement as of that date. The results of the period are not necessarily indicative of full year results or any other interim period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Summit Annual Report on Form 10-K for the year ended December 31, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 filed with the Securities and Exchange Commission on March 17, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial results of the Company's activities are reported in United States Dollars.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression of the COVID-19 pandemic continues to evolve and its enduring impact on the Company's business remains uncertain. Management believes the estimates and assumptions underlying its unaudited interim financial statements are reasonable and supportable based on the information available as of June 30, 2022, however, the extent to which the COVID-19 pandemic impacts the Company's financial results for the remainder of 2022 and beyond will depend on future developments that are highly uncertain and cannot be predicted at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2790000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
1806000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
2009000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8900000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10399000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
179000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
170000 usd
CY2022Q2 us-gaap Assets
Assets
95718000 usd
CY2021Q4 us-gaap Assets
Assets
113374000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3574000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4374000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5513000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7197000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1906000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4125000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
684000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1091000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3231000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7939000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
265000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
897000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15173000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25623000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1322000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1691000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2594000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2776000 usd
CY2022Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25312000 usd
CY2021Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0 usd
CY2022Q2 us-gaap Liabilities
Liabilities
44401000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
30090000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98122356 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98122356 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98039540 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98039540 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
981000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
980000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
391220000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
384049000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3168000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2197000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337716000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299548000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51317000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83284000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95718000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113374000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
235000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
485000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
249000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9008000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23923000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29564000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42302000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6933000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5984000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13592000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10169000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
15941000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
29907000 usd
us-gaap Operating Expenses
OperatingExpenses
43156000 usd
us-gaap Operating Expenses
OperatingExpenses
52471000 usd
CY2022Q2 us-gaap Other Operating Income
OtherOperatingIncome
3014000 usd
CY2021Q2 us-gaap Other Operating Income
OtherOperatingIncome
6120000 usd
us-gaap Other Operating Income
OtherOperatingIncome
7821000 usd
us-gaap Other Operating Income
OtherOperatingIncome
11569000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12692000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23730000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-34850000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-40653000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4079000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-686000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3318000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1251000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16771000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
us-gaap Net Income Loss
NetIncomeLoss
-41904000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99654092 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99654092 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92065957 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92065957 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99627701 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99627701 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88110285 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88110285 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16771000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
us-gaap Net Income Loss
NetIncomeLoss
-41904000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
789000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
540000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-971000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1215000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15982000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23876000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39139000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40689000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64407000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2496000 usd
CY2022Q2 smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
396000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
789000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16771000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51317000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83284000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
187000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6492000 usd
smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
493000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-971000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51317000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
64405000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
118000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74882000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
241000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3672000 usd
CY2021Q2 smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
103000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
540000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119427000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79453000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
118000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74882000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1138000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4540000 usd
smmt Adjustments To Additional Paid In Capital Imputed Interest Expense Related Party
AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty
103000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1215000 usd
us-gaap Net Income Loss
NetIncomeLoss
-41904000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119427000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
us-gaap Net Income Loss
NetIncomeLoss
-41904000 usd
smmt Interest Expense Income Noncash
InterestExpenseIncomeNoncash
941000 usd
smmt Interest Expense Income Noncash
InterestExpenseIncomeNoncash
315000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2366000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1495000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
558000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
470000 usd
us-gaap Depreciation
Depreciation
168000 usd
us-gaap Depreciation
Depreciation
170000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
480000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
512000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6492000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4540000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1160000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
704000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1231000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3968000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1383000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-195000 usd
smmt Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
2426000 usd
smmt Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
7854000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4132000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1554000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-721000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
672000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1078000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3730000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3085000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-453000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
27000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-594000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-451000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38218000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39843000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
654000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
190000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-654000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-190000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
105000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
110000000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
110000000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
54000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
187000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1138000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25187000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75979000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-771000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1023000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14456000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36969000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71791000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66417000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57335000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103386000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
85000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
smmt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
smmt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
13000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2124000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16771000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38218000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337716000 usd
CY2022Q2 us-gaap Cash
Cash
57335000 usd
CY2022Q2 smmt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
16455000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
238000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q2 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
2 country
CY2022Q2 us-gaap Noncurrent Assets
NoncurrentAssets
3112000 usd
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
3484000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7939000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3231000 usd
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7140000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7939000 usd
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8939000 usd
smmt Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
252000 usd
smmt Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
2027000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4370000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3580000 usd
smmt Contract With Customer Liability Foreign Currency Translation
ContractWithCustomerLiabilityForeignCurrencyTranslation
-590000 usd
smmt Contract With Customer Liability Foreign Currency Translation
ContractWithCustomerLiabilityForeignCurrencyTranslation
119000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3231000 usd
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7505000 usd
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8370000 usd
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
569000 usd
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
365000 usd
CY2022Q2 smmt Research And Development Tax Credit
ResearchAndDevelopmentTaxCredit
810000 usd
CY2021Q2 smmt Research And Development Tax Credit
ResearchAndDevelopmentTaxCredit
4204000 usd
smmt Research And Development Tax Credit
ResearchAndDevelopmentTaxCredit
2506000 usd
smmt Research And Development Tax Credit
ResearchAndDevelopmentTaxCredit
7883000 usd
CY2022Q2 us-gaap Other Operating Income
OtherOperatingIncome
3014000 usd
CY2021Q2 us-gaap Other Operating Income
OtherOperatingIncome
6120000 usd
us-gaap Other Operating Income
OtherOperatingIncome
7821000 usd
us-gaap Other Operating Income
OtherOperatingIncome
11569000 usd
CY2022Q2 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
14132000 usd
CY2022Q2 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
2323000 usd
CY2021Q4 smmt Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
15695000 usd
CY2021Q4 smmt Research And Development Tax Credit Receivable Noncurrent
ResearchAndDevelopmentTaxCreditReceivableNoncurrent
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16771000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-24416000 usd
us-gaap Net Income Loss
NetIncomeLoss
-38168000 usd
us-gaap Net Income Loss
NetIncomeLoss
-41904000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99654092 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92065957 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99627701 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88110285 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99654092 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92065957 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99627701 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88110285 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23074564 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11054234 shares
CY2022Q2 us-gaap Goodwill
Goodwill
1806000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
2009000 usd
CY2022Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
17948000 usd
CY2022Q2 smmt Finite Lived Intangible Assets Accumulated Amortization And Impairment
FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
9048000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8900000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19963000 usd
CY2021Q4 smmt Finite Lived Intangible Assets Accumulated Amortization And Impairment
FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment
9564000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10399000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
232000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
480000 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
257000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
512000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-686000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2124000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2017000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2790000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
377000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
589000 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
344000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
483000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3318000 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3412000 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-389000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2482000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-851000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
653000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
216000 usd
us-gaap Interest Expense
InterestExpense
805000 usd
us-gaap Interest Expense
InterestExpense
242000 usd
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14000 usd
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
81000 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
31000 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
158000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4079000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1251000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4079000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3318000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13797556 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6126381 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2784349 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11995 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17127593 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.14
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2390153 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.65
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q2 us-gaap Share Price
SharePrice
1.06
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2496000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3671000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6492000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4540000 usd
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
0 usd
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
0 usd

Files In Submission

Name View Source Status
0001599298-22-000095-index-headers.html Edgar Link pending
0001599298-22-000095-index.html Edgar Link pending
0001599298-22-000095.txt Edgar Link pending
0001599298-22-000095-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
smmt-20220630_pre.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smmt-20220630.htm Edgar Link pending
smmt-20220630.xsd Edgar Link pending
smmt-20220630_lab.xml Edgar Link unprocessable
smmt-20220630_cal.xml Edgar Link unprocessable
smmt-20220630_htm.xml Edgar Link completed
sum-ex311_20220630xduggan.htm Edgar Link pending
sum-ex312_20220630xzanganeh.htm Edgar Link pending
sum-ex313_20220630xdhingra.htm Edgar Link pending
sum-ex321_20220630x10q.htm Edgar Link pending
smmt-20220630_def.xml Edgar Link unprocessable